Selected Group Publications

2017

Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). Version 2. Guarch R, Cortés JM, Lawrie CH, López JI. F1000Res. 2016 Aug 17 [revised 2016 Jan 1];5:2020

Nanoparticle-Based Discrimination of Single-Nucleotide Polymorphism in Long DNA Sequences. Sanromán-Iglesias M, Lawrie CH, Liz-Marzán LM, Grzelczak M.  Bioconjug Chem. 2017 Mar 1. [Epub ahead of print]

Comparison of abnormal cell flagging of the hematology analyzers Sysmex XN and Sysmex XE-5000 in oncohematologic patients. Furundarena JR, Sainz M, Uranga A, Cuevas L, Lopez I, Zubicaray J, Bizjak A, Robado N, Araiz M. Int J Lab Hematol. 2017 Feb;39(1):58-67

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Chanan-Khan A, Egyed M, Robak T, Martinelli de Oliveira FA, Echeveste MA, Dolan S, Desjardins P, Blonski JZ, Mei J, Golany N, Zhang J, Gribben JG. Leukemia. 2017 Feb 17 [Epub ahead of print]

Differentiation stage of myeloma plasma cells: biological and clinical significance. Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF. Leukemia. 2017 Feb;31(2):382-392

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, van den Brink MR, Young JW, O’Reilly RJ, Giralt SA, Perales MA. Biol Blood Marrow Transplant. 2017 Jan;23(1):67-74

2016

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Mateos MV, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Palomera L, de Arriba F, Esseltine DL, Cakana A, Pei L, van de Velde H, Miguel JS. Ann Hematol. 2016 Dec;95(12):2033-2041

SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression. Santos JC, Carrasco-Garcia E, Garcia-Puga M, Aldaz P, Montes M, Fernandez-Reyes M, de Oliveira CC, Lawrie CH, Araúzo-Bravo MJ, Ribeiro ML, Matheu A. Cancer Res. 2016 Nov 15;76(22):6735-6746

Challenges, opportunities and best practice when using miRNA as disease biomarkers in liquid biopsies. Fernandez-Mercado M, Lawrie CH. JSM Biotechnol Bioeng 3(4): 1061

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. Houédé N, Locker G, Lucas C, Parra HS, Basso U, Spaeth D, Tambaro R, Basterretxea L, Morelli F, Theodore C, Lusuardi L, Lainez N, Guillot A, Tonini G, Bielle J, Del Muro XG. BMC Cancer. 2016 Sep 23;16(1):752

Aberrant expression of MicroRNAs in B-cell lymphomas. Sole C, Larrea E, Manterola L, Goicoechea I, Armesto M, Arestin M, Caffarel M, Araujo A, Fernandez-Mercado M, Araiz M, Lawrie CH. Microrna. 2016 Aug 25 [Epub ahead of print]

Stratification and therapeutic potential of PML in metastatic breast cancer. Martín-Martín N, Piva M, Urosevic J, Aldaz P, Sutherland JD, Fernández-Ruiz S, Arreal L, Torrano V, Cortazar AR, Planet E, Guiu M, Radosevic-Robin N, Garcia S, Macías I, Salvador F, Domenici G, Rueda OM, Zabala-Letona A, Arruabarrena-Aristorena A, Zúñiga-García P, Caro-Maldonado A, Valcárcel-Jiménez L, Sánchez-Mosquera P, Varela-Rey M, Martínez-Chantar ML, Anguita J, Ibrahim YH, Scaltriti M, Lawrie CH, Aransay AM, Iovanna JL, Baselga J, Caldas C, Barrio R, Serra V, Vivanco Md, Matheu A, Gomis RR, Carracedo A. Nat Commun. 2016 Aug 24;7:12595

Differentiation stage of myeloma plasma cells: biological and clinical significance. Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Aguirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, Miguel JF. Leukemia. 2016 Aug 1

Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. Kucia-Tran JA, Tulkki V, Smith S, Scarpini CG, Hughes K, Araujo AM, Yan KY, Botthof J, Pérez-Gómez E, Quintanilla M, Cuschieri K, Caffarel MM, Coleman N.  Brit J Cancer. 2016 Jul 12;115(2):212-22

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martín-Ramos ML, Martinez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosiñol L, Echeveste MA, Martinez R, Gironella M, Oriol A, Cabrera C, Martin J, Bargay J, Encinas C, Gonzalez Y, Van Dongen JJ, Orfao A, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF.  Blood. 2016 Jun 23;127(25):3165-74

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, García-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF. Blood. 2016 Apr 14;127(15):1896-906

mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. Garros-Regulez L, Aldaz P, Arrizabalaga O, Moncho-Amor V, Carrasco-Garcia E, Manterola L, Moreno-Cugnon L, Barrena C, Villanua J, Ruiz I, Pollard S, Lovell-Badge R, Sampron N, Garcia I, Matheu A. Expert Opin Ther Targets. 2016;20(4):393-405

New concepts in cancer biomarkers: circulating miRNAs and liquid biopsies. Larrea E, Sole C, Manterola L, Goicoechea I, Armesto M, Arestin M, Caffarel MM, Araujo A, Fernandez-Mercado MLawrie CH. Int J Mol Sci. 2016 Apr 27;17(5) (special issue on “Liquid Biopsy for Clinical Application”)

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, Echeveste MA, …; TOURMALINE-MM1 Study Group. N Engl J Med. 2016 Apr 28;374(17):1621-34

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D. BMC Cancer. 2016 Feb 22;16:135

Why some tumours trigger neovascularisation and others don’t: the story thus so far. Aghidibe O, Leek RD, Fernandez-Mercado M, Hu J, Snell C, Gatter KC, Harris AL, Pezzella F.  Chinese Journal of Cancer 2016 Feb 12;35:18 (special issue on “Cancer and Vessels”)

Targeted re-sequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. Pellagatti A, Roy S, Genua CD, Burns A, McGraw K, Valletta S, Larrayoz MJ, Fernandez-Mercado M, Mason J, Killick S, Mecucci C, Calasanz MJ, List A, Schuh A, Boultwood J.  Leukemia. 2016 Jan;30(1):248-50

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, Bladé J, Lahuerta JJ, San-Miguel J. Blood. 2016 Jan 28;127(4):420-5

2015

Transcriptional-Repression by a novel HDAC4-RelB-p52 complex regulates Multiple Myeloma Survival and growth. Vallabhapurapu SD, Noothi SK, Pullum D, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Plas DR, Orlowski R, Chesi M, Kuehl WM, Bergsagel LP, Karin M & Vallabhapurapu S. Nature Commun 2015 Oct 12;6:8428

MicroRNAs in Lymphoma: regulatory role and biomarker potential. Fernandez-Mercado M, Manterola L, Lawrie CH. Current Genomics. 2015 201;16(5)

The circulating transcriptome as a source of non-invasive cancer biomarkers: Concepts and controversies of non-coding and coding RNA in body fluids. Fernandez-Mercado M, Manterola L, Larrea E, Goicoechea I, Arestin M, Armesto M, Otaegui D, Lawrie CH. J Cell Mol Med. 2015 Oct;19(10):2307-23

Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. Wong KK, Ch’ng ES, Loo SK, Husin A, Arestin M, Møller MB, Pedersen LM, Puente Pomposo M, Gaafar A, Banham AH, Green TM, Lawrie CH.  Exp Mol Pathol. 2015 99(3):537-545 

Conjugated polymers as molecular gates for light-controlled release of gold nanoparticles. Sanromán-Iglesias M, Zhang KA, Chuvilin A, Lawrie CH, Grzelczak M, Liz-Marzán LM.  ACS Appl Mater Interfaces. 2015 Jul 29;7(29):15692-5

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Martínez-López J, Paiva B, López-Anglada L, Mateos MV, Cedena T, Vidríales MB, Sáez-Gómez MA, Contreras T, Oriol A, Rapado I, Teruel AI, Cordón L, Blanchard MJ, Bengoechea E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao A, Bladé J, San Miguel JF, Lahuerta JJ. Blood. 2015 Jun 18

Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, Evens AM, Laport GG, Moskowitz CH, Popat U, Reddy NM, Shea TC, Vose JM, Schriber J, Savani BN, Carpenter PA.  Biol Blood Marrow Transplant. 2015 Jun;21(6):971-983

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Paíno T, Paiva B, Sayagués JM, Mota I, Carvalheiro T, Corchete LA, Aires-Mejía I, Pérez JJ, Sanchez ML, Barcena P, Ocio EM, San-Segundo L, Sarasquete ME, García-Sanz R, Vidriales MB, Oriol A, Hernández MT, Echeveste MA, Paiva A, Blade J, Lahuerta JJ, Orfao A, Mateos MV, Gutiérrez NC, San-Miguel JF.  Leukemia. 2015 May;29(5):1186-94

MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. Erice O, Smith MP, White R, Goicoechea I, Barriuso J, Jones C, Margison GP, Acosta JC, Wellbrock C, Arozarena I. Mol Cancer Ther. 2015 May;14(5):1236-46

Written in Blood: kissing disease miRNAs could predict outcome of patients with chronic lymphocytic leukemia. Lawrie CH. eBiomedicine. 2015 May 12;2(6):489-90

Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer. Pérez-Gómez E, Andradas C, Blasco-Benito S, Caffarel MM, García-Taboada E, Villa-Morales M, Moreno E, Hamann S, Martín-Villar E, Flores JM, Wenners A, Alkatout I, Klapper W, Röcken C, Bronsert P, Stickeler E, Staebler A, Bauer M, Arnold N, Soriano J, Pérez-Martínez M, Megías D, Moreno-Bueno G, Ortega-Gutiérrez S, Artola M, Vázquez-Villa H, Quintanilla M, Fernández-Piqueras J, Canela EI, McCormick PJ, Guzmán M, Sánchez C. J Natl Cancer Inst. 2015 Apr 8;107(6)

Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. Mateos MV, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J, Martínez-López J, Echeveste MA, Sarrá J, Ocio E, Ramírez G, Martínez R, Palomera L, Payer A, Iglesias R, De la Rubia J, Alegre A, Chinea AI, Bladé J, Lahuerta JJ, San Miguel JF. Haematologica. 2015 Apr 24

Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. Ceberio I, Devlin SM, Sauter C, Barker JN, Castro-Malaspina H, Giralt S, Ponce DM, Lechner L, Maloy MA, Goldberg JD, Perales MA. Leuk Lymphoma. 2015 Mar;56(3):663-70

Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. Ceberio I, Dai K, Devlin SM, Barker JN, Castro-Malaspina H, Goldberg JD, Giralt S, Adel NG, Perales MA. Bone Marrow Transplant. 2015 Mar;50(3):438-43

MicroRNAs as B-Cell lymphoma biomarkersManterola L, Fernandez-Mercado M, Larrea E, Goicoechea I, Arestin M, Armesto M, Hernandez L, Lawrie CH. Blood and Lymphatic Cancer: Targets and Therapy. 2015 Feb (5):25-34

2014

Update of the GEM2005 trial comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Mateos MV, Oriol A, Martínez-López J, Teruel AI, López de la Guía A, López J, Bengoechea E, Pérez M, Martínez R, Palomera L, de Arriba F, González Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Martín-Mateos ML, Paiva B, Montalbán MA, Bladé J, Lahuerta JJ, San-Miguel JF. Blood. 2014 Aug 7

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. Arozarena I, Goicoechea I, Erice O, Ferguson J, Margison GP, Wellbrock C. Mol Cancer. 2014 Jun 19;13:154

Targeted Inhibition of Prostate Cancer Metastases with an RNA Aptamer to Prostate-specific Membrane Antigen. Dassie JP, Hernandez LI, Thomas GS, Long ME, Rockey WM, Howell CA, Chen Y, Hernandez FJ, Liu XY, Wilson ME, Allen LA, Vaena DA, Meyerholz DK, Giangrande PH. Mol Ther. 2014 Jun 23

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia. Pellagatti A, Fernandez-Mercado M, Di Genua C, Larrayoz MJ, Killick S, Dolatshad H, Burns A, Calasanz MJ, Schuh A, Boultwood J. Leukemia. 2014 May;28(5):1148-51

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Wong KK, Gascoyne DM, Brown PJ, Soilleux EJ, Snell C, Chen H, Lyne L, Lawrie CH, Gascoyne RD, Pedersen LM, Møller MB, Pulford K, Murphy D, Green TM, Banham AH. Leukemia. 2014 Feb;28(2):470

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, Tawana K, Popov N, O’Riain C, O’Shea D, Carlotti E, Davies A, Lawrie CH, Matolcsy A, Calaminici M, Norton A, Byers RJ, Mein C, Stupka E, Lister TA, Lenz G, Montoto S, Gribben JG, Fan Y, Grosschedl R, Chelala C, Fitzgibbon J. Nat Genet. 2014 Feb;46(2):176-81

The Presence of Mutations in the K-RAS Gene Does Not Affect Survival after Resection of Pulmonary Metastases from Colorectal Cancer. Zabaleta J, Aguinagalde B, Izquierdo JM, Bazterargui N, Laguna SM, Martin-Arruti M, Lobo C, Emparanza JI. ISRN Surg. 2014 Feb 4;2014:157586

A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Manterola L, Guruceaga E, Gállego Pérez-Larraya J, González-Huarriz M, Jauregui P, Tejada S, Diez-Valle R, Segura V, Samprón N, Barrena C, Ruiz I, Agirre A, Ayuso A, Rodríguez J, González A, Xipell E, Matheu A, López de Munain A, Tuñón T, Zazpe I, García-Foncillas J, Paris S, Delattre JY, Alonso MM. Neuro Oncol. 2014 Jan 22

Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes. Lawrie CH, Larrea E, Larrinaga G, Goicoechea I, Arestin M, Fernandez-Mercado M, Hes O, Cáceres F, Manterola L, López JI. J Pathol. 2014 Jan;232(1):32-42

2013

Potluri, P., Noothi, S.K., Vallabhapurapu, S.D. Yoon, S-O, Driscoll, JJ,  Lawrie, CH,  Vallabhapurapu, S. (2013) PLoS ONE. Transcriptional Repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple Myeloma. 8(7): e66121.

Lawrie, CH, Larrea, E., Larrinaga, G., Goicoechea, I., Cáceres, F., Arestin, M., Fernandez, M., Manterola, L., & López, J.I. (2013) Journal of Pathology. Clear cell papillary renal cell carcinoma has a distinct non-coding RNA expression profile characterised by over-expression of the miR-200 cluster. (DOI: 10.1002/path.4296)

Caramuta, S., Linkiat, L., Özata, D.M., Akçakaya, P., Georgii-Hemming, P., Xie, H., Amini, R., Lawrie, C.H., Enblad, G., Larsson, C., Berglund, M., Lui, W-O. (2013) Blood Cancer Journal Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. 3 e152

Carrasco, E., Sampron, N., Aldaz, P., Arrizabalaga, O., Vilauna, J., Barrena, C., Ruiz, I., Arrazola, M., Lawrie, C.H., Matheu, A. (2013) Recent patents on anti-cancer drug discovery. Therapeutic strategies targeting glioblastoma stem cells. 8(3):216-27

Lawrie, C.H. (2013) Blood Reviews. MicroRNAs in hematological malignancies. 27: 143-54

Lawrie, C.H. (2013) British Journal of Haematology. MicroRNAs and lymphomagenesis. 160(5): 571-81

Fernandez-Mercado M, Pellagatti A, Di Genua C, Larrayoz MJ, Winkelmann N, Aranaz P, Burns A, Schuh A, Calasanz MJ, Cross NCP and Boultwood J. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression. British Journal of Haematology. Br J Haematol. 2013 Oct;163(2):235-239

Fernandez-Mercado M, Burns A, Pellagatti A, Giagounidis A, Aul C, Killick S, Wainscoat JS, Schuh A and Boultwood J. Targeted resequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica. 2013 Dec;98(12):1856-64

Davies C, Yip BH, Fernandez-Mercado M, Woll PS, Agirre X, Prosper F, Jacobsen SE, Vyas P, Wainscoat JS, Pellagatti A and Boultwood J. Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34+ cells. 2013 British Journal of Haematology. 160(6):842-50

Manterola L, Hernando-Rodriguez M, Ruiz A, Apraiz A, Arrizabalaga O, Vellon L., Cavaliere F., Alberdi E., Lacerda HM, Jimenez S, Parada L, Matute C, Zugaza JL. 1-42 β-amyloid peptide (Aβ1-42) requires PDK1/nPKCs/Rac 1 pathway to induce neuronal death. Translational Psychiatry. 2013 Jan 22;3:e219

2012

Ballabio, E., Armesto,M., Breeze, C.E.,  Manterola,L., Arestin,M.,  Tramonti,D., Hatton, C.S.R., Lawrie, C.H.(2012) Blood Cancer Journal. Bortezomib action in multiple myeloma: MicroRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)? 2 : e83.

Lawrie, C.H. (2012) Myeloid disorders in Practice. MicroRNAs: back to basics. 6 (2): 3-5.

Lawrie, C.H. (2012) Cancers. Guest editor and editorial for special edition entitled ´Leukemias´.4(2): 600-632

Benner,M.F., Ballabio, E., van Kester, M.S., Chen, X-H, Saunders, N.J.,   Vermeer, M.H, Willemze, R., Lawrie, C.H.*, Tensen, C.P.*, (2012) Experimental Dermatology.  MicroRNA expression profiling of cutaneous anaplastic large cell lymphoma shows differences with tumor stage mycosis fungoides. 21(8):632-4

Lawrie, C.H., Ballabio, E., Soilleux, E., Sington, J., Hatton, C.S.R., Tzankov, A., Dirnhofer, S. (2012) Histopathology.  Inter- and Intra-Observational Variability in Immunohistochemistry: A Multi-Center Analysis of Diffuse Large B-Cell Lymphoma (DLBCL) Staining. 61 (1) 18-25

Fernandez-Mercado M, Yip BH, Pellagatti S, Davies C, Larrayoz MJ, Kondo T, Pérez C, Killick S, McDonald EJ, Odero MD, Agirre X, Prósper F, Calasanz MJ, Wainscoat JS, Boultwood J. Mutation patterns of 16 genes in primary and secondary AML with normal cytogenetics. PLoS ONE.  2012;7(8):e42334.

Nikpour M, Scharenberg C, Liu A, Conte S, Karimi M, Mortera-Blanco T, Giai V, Fernandez-Mercado M, Papaemmanuil E, Högstrand K, Jansson M, Vedin I, Stephen Wainscoat J, Campbell P, Cazzola M, Boultwood J, Grandien A, Hellström-Lindberg E. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia. 2012 27(4):889-96.

Pérez C, Martínez-Calle N, Martín-Subero JI, Segura V, Delabesse E, Fernandez-Mercado M, Garate L, Alvarez S, Rifon J, Varea S, Boultwood J, Wainscoat JS, Cigudosa JC, Calasanz MJ, Cross NC, Prósper F, Agirre X. TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia. PLoS ONE. 2012;7(2):e31605

Yip BH, Pellagatti A, Vuppusetty C, Giagounidis A,  Germing U, Lamikanra AA, Roberts DJ, Fernandez-Mercado M, McDonald EJ, Killick S, Wainscoat JS,  Boultwood J. Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia. 2012. 26(9):2154-8

Matheu A, Collado M, Wise C, Manterola L, Cekaite L, Tye A, Canamero M, Bujanda L, Schedl A, Cheah K, Skotheim R, Lothe R, Lopez de Munain A, Briscoe J, Serrano M, and Lovell-Badge R.
Oncogenicity of the Developmental Transcription Factor Sox9.
Cancer Research. 2012. 72(5):1301-1315.

2011

Chi, J., Ballabio, E., Chen, X.-H., Kušec, R., Taylor, S., Hays, D., Tramonti, D., Ross, F.M., Saunders, N.J., Pezzella, F., Littlewood, T, Boultwood, J., Wainscoat, J.S., Hatton, C.S.R, Lawrie, C.H. (2011) Biology Direct. MicroRNA Expression in Multiple Myeloma is Associated with Genetic Subtype, Isotype and Survival. 6 (1): e23.van Kester, M.S., Ballabio, E., Benner,M.F.,  Chen, X-H, Saunders, N.J.,   van der Fits, L., van Doorn, R., Vermeer, M.H,, Willemze, R., Tensen, C.P., Lawrie, C.H. (2011) Molecular Oncology.  MicroRNA expression profiling of mycosis fungoides. 5 (3): 273-280

Cooper, CD*,Lawrie CH*, Liggins, A, Collins, G, Pulford, K, Banham, AH (2011) PLoS ONE. Detection of immunogenic proteins in peripheral T cell lymphoma by SEREX. 6(8): e23916

Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, Lopez de Munain A, Sampron N, Aramburu A, Tejada-Solís S, Vicente C, Odero MD, Bandrés E, García-Foncillas J, Idoate MA, Lang FF, Fueyo J, Gomez-Manzano C. Genetic and Epigenetic modifications of Sox2 Contribute to the Invasive Phenotype of Malignant Gliomas Plos One. 2011. 6(11):e26740

Díaz-Valdés N, Manterola L, Belsúe V, Riezu-Boj JI, Larrea E, Echeverria I, Llópiz D, López-Sagaseta J, Lerat H, Pawlotsky JM, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of Interleukin 10. Hepatology. 2011; 53(1):23-31.

2010

Ballabio, E., Mitchell, T., van Kester, M.S., Taylor, S., Dunlop, H.M., Chi, J., Tosi, I, Vermeer, M.H, Tramonti, D., Saunders, N.J., Boultwood, J., Wainscoat, J.S., Pezzella, F., Whittaker, S.J., Tensen, C.P. Hatton, C.S.R., Lawrie, C.H. (2010) Blood. MicroRNA expression in Sézary syndrome: Identification, function and diagnostic potential. 116(7): 1105-13

Ballabio, E., Chi, J., Roncador, G., Banham, AH, Hatton, C.S.R., Lawrie, C.H. (2010) Clinical Cancer Research. Comparison of Choi and Hans’algorithms by immunohistochemistry and qRT-PCR. 16(14): 3805-6

Lawrie, C.H. (2010) British Journal of Haematology. MicroRNA control of erythropoiesis and erythroid disorders. 150 (2): 144-151

Campbell, A, Lyne, L, Brown, PJ, Launchbury, R, Bigone, P, Chi, J, Roncador, G, Lawrie, CH, Gatter, K, Kusec, R, Banham, AH. (2010) British Journal of Haematology. Aberrant expression of the speech and language gene FOXP2 in neoplastic plasma cells. 149 (2): 221-230.

Ait-Tahar, K., Liggins, A.P., Collins, G., Campbell, A., Barnardo, M., Lawrie, C.H, Moir, D., Hatton, C.S.R., Banham, A.H. and Pulford, K. (2010) Haematologica. CD4 Th responses to the PASD1 protein in patients with diffuse large B cell lymphoma. 96(1): 78-86.

Brown, P.J., Campbell, A.J., Lyne, L., Chi, J., Lawrie, C.H., Kusec, R., Banham, A.H. (2010) Open Leukemia Journal.Expression of the FOXP1 transcription factor is post-transcriptionally silenced in normal and malignant CD138+ plasma cells. 3:16-23.

Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M , Fernandez-Santamaria C, Calasanz MJ, Larrayoz MJ, Garcia-Delgado M, Giagounidis A, Malcovati L, Della Porta MG, Jädersten M, Killick S, Hellström-Lindberg E, Cazzola M, Wainscoat JS. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010;24(5):1062-5

2009

Lawrie, C.H., Shilling, R.,Troussard, X., Cattan, H., Mossafa, H., Pezzella, F., Boultwood, J., Wainscoat, J.S. and Hatton, C.S.R (2009) Leukemia. Expression profiling of persistent polyclonal B-cell lymphocytosis (PPBL) suggests constitutive expression of the AP-1 transcription complex and down-regulation of Fas-apoptotic and TGFβ signalling pathways. 23 (3):581-3

Lawrie, C.H., Chi, J., Tramonti, D., Ballabio, E., Taylor, S., Saunders, N.J., Palazzo, S., Pezzella, F., Boultwood, J., Wainscoat, J.S. and Hatton, C.S.R. (2009) Journal of Cellular and Molecular Medicine. MicroRNA expression profiling of Diffuse Large B cell Lymphoma reveals signatures associated with immunophenotype, survival and transformation from Follicular Lymphoma. 13 (7): 1248-60

Lawrie, C.H., Ballabio, E., Dyar, O.J., Jones, M., Ventura, R., Chi, J., Tramonti, D., Pezzella, F., Boultwood, J., Wainscoat, J.S., Schuh, A., Hatton, C.S.R. (2009) British Journal of Haematology. MicroRNA expression in chronic lymphocytic leukemia. 147: 398-402

Lawrie, C.H., Cooper, C.D., Ballabio, E., Chi, J., Tramonti, D., Hatton, C.S.R. (2009) British Journal of Haematology. Aberrant expression of microRNA biosynthetic components is a common feature of haematological malignancy. 145 (4): 545-8.

Yao, Y., Smith, L.P., Y. Zhao, Lawrie, C.H., Watson, M., Nair, V (2009) Journal of General Virology. Differential expression of miRNAs in Marek’s disease virus-transformed T-lymphoma cell lines. 90 (7): 1551-9

Ait-Tahar, K., Liggins, A.P., Collins, G., Campbell, A., Barnardo, M., Lawrie, C.H, Hatton, C.S.R., Banham, A.H. and Pulford, K. (2009) British Journal of Haematology. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. 146(4):396-407.

2008

Lawrie, C.H. (2008) Journal of Cellular and Molecular Medicine. MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy? 12 (5): 1432-44.

Lawrie, C.H., Saunders, N.J., Soneji, S., Palazzo, S., Dunlop, H.M., Cooper, C.D., Brown, P.J., Troussard, X., Mossafa, H., Enver, T., Pezzella, F., Boultwood, J., Wainscoat, J.S. and Hatton, C.S.R. (2008) Leukemia. MicroRNA expression in lymphocyte development and malignancy. 22 (7): 1440-6.

Lawrie, C.H., Gal, S., Dunlop, H., Pushkaran, B., Liggins, A.P., Pulford, K., Banham, A.H., Pezzella, F., Boultwood, J., Wainscoat, J.S., Hatton, C.S.R. and Harris, A.L. (2008) British Journal of Haematology. Detection of elevated tumor-associated microRNAs in serum of patients with diffuse large B cell lymphoma. 141 (5):672-5.

Yao, Y., Zhao, Y., Xu, H., Smith, L.P., Lawrie, C.H., Watson, M., Nair, V (2008) Journal of Virology. microRNA profile of Marek’s disease virus-transformed T cell line MSB-1: Prominance of virus-encoded microRNAs. 82 (8) 4007-4015

Fernandez-Mercado M, Cebrián V, Euba B, García-Granero M, Calasanz MJ, Novo FJ, Vizmanos JL, García-Delgado M. Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms. Leukemia Research. 2008 Oct;32(10):1638-40.

2007

Lawrie, C.H., Soneji, S., Marafioti, T., Cooper, C.D.O, Paterson, J.C., Enver, T., Mager, R., Boultwood, J., Wainscoat, J.S. and Hatton, C.S.R. (2007) International Journal of Cancer. MicroRNA expression distinguishes between germinal center B cell-like (GCB) and activated B cell-like (ABC) subtypes of diffuse large B cell lymphoma. 121 (5) 1156-1161.

Lawrie, C.H. (2007) British Journal of Haematology. MicroRNAs and Haematology: Small molecules, big function. 136 (6) 503-512.

Lawrie, C.H. (2007) Expert Opinions in Biological Therapies. MicroRNA expression in lymphoma. 7 (9) 1363-1374.

Yao, Y., Zhao, Y., Xu, H., Smith, L.P., Lawrie, C.H., Zavolan, M. and Nair, V (2007) Journal of Virology. Marek’s disease virus type 2 (MDV-2)-encoded microRNAs show no sequence conservation to those encoded by MDV-1. 81 (13) 7164-7170.

Liggins, A.P., Cooper, C.D., Lawrie, C.H., Brown, P.J., Pulford, K., Banham, A.H. (2007) British Journal of Haematology. MORC4, a novel SEREX antigen that is highly expressed in diffuse large B-cell lymphoma. 138 (4) 479-86

Boultwood, J., Pellagatti, A., Cattan, H, Lawrie, C.H., Giagounidis, A.A.N., Malcovati, L., Jadersten, M., Killick, S., Cazzola, M., Hellstrom-Lindberg, E. Wainscoat, J.S. (2007) British Journal of Haematology. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 139(4):578-89

Manterola L, , Guzman-Verri C, Chaves-Olarte E, Barquero-Calvo E, de Miguel MJ, Moriyón I, Grilló MJ, Lopez-Goni I, Moreno E. The BvrR/BvrS-controlled outer membrane proteins Omp3a and Omp3b are not essential for Brucella abortus virulence. Infect Immun. 2007; 75(10):4867-74.

Books and Book chapters

Lawrie, C.H. (Editor) (2013) MicroRNAs in Medicine. Wiley & Sons, New York (ISBN 978-1-1183-0039-8), 40 Chapters  720 pages

Lawrie, C.H. (Editor) (2012) Hematology: Science and Practice. InTech Publishing, Viena, Austria (ISBN 978-953-51-0174-1), 24 Chapters, 612 pages

Lawrie, C.H. (2013) “MicroRNAs in blood cancers” Chapter 6 in MicroRNAs as key regulators of oncogenesis. Springer, New York, US.

Otaegui, D and Lawrie, C.H. (2013) “MicroRNAs as cancer biomarkers” Chapter 11 in Applied RNAi: From Fundamental Research to Therapeutic Applications. Horizon Press, Norwich, UK (ISBN 978-1-908230-43-0).

Armesto, M and Lawrie, C.H. (2013) “West Nile Virus transmission by ticks: Experimental oddity or unexplored reality?” Chapter 12 in Advances in Virus Research. iConcept Press, Queensland, Australia (ISBN: 978-14775550-4-0).

Carrasco, E., Sampron, N., Aldaz, P., Arrizabalaga, O., Vilauna, J., Barrena, C., Ruiz, I., Arrazola, M., Lawrie, C.H., Matheu, A. (2014). Therapeutic strategies targeting glioblastoma stem cells. Chapter ? in Topics in Anti-Cancer Research (Volume 3). Bentham Science Publishers, IL, US

Lawrie, C.H. (2013) “MicroRNAs: A brief introduction” Chapter 1 in MicroRNAs in Medicine (Editor Lawrie,C.H.). Wiley & Sons, New York (ISBN 978-1-1183-0039-8) Pg. 1-16.

Lawrie, C.H. (2012) “MicroRNA Expression in Follicular Lymphoma” Chapter 15 in Hematology: Science and Practice (Editor Lawrie,C.H.). InTech Publishing, Vienna, Austria. Pg. 393-408.